Moderna: positive data for vaccine in 6-12 year olds

(CercleFinance.com) - Moderna yesterday announced positive interim data from a Phase 2/3 study of its Covid vaccine candidate in 6-12 year olds.


The analysis showed a robust neutralizing antibody response after two doses of the mRNA-1273 serum (50 mcg) with a favourable safety profile. Therefore, the study met its primary immunogenicity endpoints, it said.

Moderna now plans to submit this data to the US FDA, the European Medicines Agency (EMA) and other global regulators.

The Moderna stock jumped 7% in New York yesterday, closing just shy of 350 dollars.


Copyright (c) 2021 CercleFinance.com. All rights reserved.